PYNNACLE II期临床试验方案：rezatapopt （PC14586）单药治疗TP53 Y220C突变的晚期或转移性实体瘤。

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-11 DOI:10.1080/14796694.2025.2557176

Alison M Schram, Marc Fellous, Kim LeDuke, Anita Schmid, Ecaterina E Dumbrava

引用次数: 0

摘要

临床试验注册：NCT04585750 （ClinicalTrials.gov）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation.

Clinical trial registration: NCT04585750 (ClinicalTrials.gov).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.